IGF1R and prostate adenocarcinoma: Studies have found that low FUS expression in prostate cancer cell lines VCaP and LNCaP can phenomenally inhibit the expression of androgen AR and its downstream targets IGF1R and EGFR, thus inhibiting PRAD proliferation [19].